Conference Paper: Impact of antiviral therapy on the survival outcome of patients after major hepatectomy for hepatitis B-related hepatocellular carcinoma

File Download Links for fulltext
(May Require Subscription)
Supplementary
  • Basic View
  • Metadata View
  • XML View
TitleImpact of antiviral therapy on the survival outcome of patients after major hepatectomy for hepatitis B-related hepatocellular carcinoma
AuthorsChan, ACY
Chok, K
Yuen, WK
Poon, R
Lo, CM
Fan, ST
KeywordsMedical sciences
Endocrinology
Issue Date2011
PublisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
CitationThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 419-420, abstract no. PP29-05 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s12072-010-9241-z
AbstractBACKGROUND: Although the therapeutic benefit of anti-viral treatment in the management of chronic hepatitis B infection (HBV) is well established, it remains uncertain if commencement of anti-viral therapy after hepatectomy in anti-viral naïve patients with hepatocellular carcinoma (HCC) would improve their survival outcome. METHODS: From September 2003 to December 2007, 42 patients (i.e. treatment group) were given Lamivudine (n = 39) or Entecavir(n = 4) after hepatectomy for HBV-related HCC. All these patients were anti-viral naïve before hepatectomy. Their preoperative data, tumor characteristics and survival outcome were compared with 94 patients without any antiviral treatment after hepatectomy (i.e. control group). RESULTS: The median age for treatment and control group were 57 and 55 years old respectively (P = 0.77). Patient demographics, preoperative liver function, tumor characteristics, liver function at the time of tumor recurrence were comparable between the two groups. Both disease-free and overall survival rates were significantly improved in the treatment group. The 1-, 3-, and 5-year overall survival rate in the treatment group was 88.1, 79.1, and 71.2% respectively, and in the control group was 76.5, 47.5, and 43.5% respectively (P = 0.005). The 1-, 3- and 5-year disease-free survival rate in the treatment group was 66.5, 51.4, and 51.4% respectively, and in the control group was 48.9, 33.8, and 33.8% respectively (P = 0.05). Subgroup analysis stratified against tumour stage and portal vein status showed that post-hepatectomy antiviral treatment confers a significant survival benefit in AJCC stage I/II tumours or HCCs without portal vein invasion. CONCLUSION: Anti-viral naïve HBV carriers could still benefit from the therapeutic effect of anti-viral treatment after curative treatment for hepatocellular carcinoma.
DescriptionOral Presentations
ISSN1936-0533
2011 Impact Factor: 2.645
2011 SCImago Journal Rankings: 0.244
DOIhttp://dx.doi.org/10.1007/s12072-010-9241-z
ISI Accession Number IDWOS:000300105300001
DC Field
Value
dc.contributor.authorChan, ACY
dc.contributor.authorChok, K
dc.contributor.authorYuen, WK
dc.contributor.authorPoon, R
dc.contributor.authorLo, CM
dc.contributor.authorFan, ST
dc.date.accessioned2011-07-27T02:02:44Z
dc.date.available2011-07-27T02:02:44Z
dc.date.issued2011
dc.description.abstractBACKGROUND: Although the therapeutic benefit of anti-viral treatment in the management of chronic hepatitis B infection (HBV) is well established, it remains uncertain if commencement of anti-viral therapy after hepatectomy in anti-viral naïve patients with hepatocellular carcinoma (HCC) would improve their survival outcome. METHODS: From September 2003 to December 2007, 42 patients (i.e. treatment group) were given Lamivudine (n = 39) or Entecavir(n = 4) after hepatectomy for HBV-related HCC. All these patients were anti-viral naïve before hepatectomy. Their preoperative data, tumor characteristics and survival outcome were compared with 94 patients without any antiviral treatment after hepatectomy (i.e. control group). RESULTS: The median age for treatment and control group were 57 and 55 years old respectively (P = 0.77). Patient demographics, preoperative liver function, tumor characteristics, liver function at the time of tumor recurrence were comparable between the two groups. Both disease-free and overall survival rates were significantly improved in the treatment group. The 1-, 3-, and 5-year overall survival rate in the treatment group was 88.1, 79.1, and 71.2% respectively, and in the control group was 76.5, 47.5, and 43.5% respectively (P = 0.005). The 1-, 3- and 5-year disease-free survival rate in the treatment group was 66.5, 51.4, and 51.4% respectively, and in the control group was 48.9, 33.8, and 33.8% respectively (P = 0.05). Subgroup analysis stratified against tumour stage and portal vein status showed that post-hepatectomy antiviral treatment confers a significant survival benefit in AJCC stage I/II tumours or HCCs without portal vein invasion. CONCLUSION: Anti-viral naïve HBV carriers could still benefit from the therapeutic effect of anti-viral treatment after curative treatment for hepatocellular carcinoma.
dc.descriptionOral Presentations
dc.description.otherThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 419-420, abstract no. PP29-05
dc.identifier.citationThe 21st Conferece of the Asian Pacific Association for the Study of the Liver (APASL 2011), Bangkok, Thailand, 17-20 February 2011. In Hepatology International, 2011, v. 5 n. 1, p. 419-420, abstract no. PP29-05 [How to Cite?]
DOI: http://dx.doi.org/10.1007/s12072-010-9241-z
dc.identifier.doihttp://dx.doi.org/10.1007/s12072-010-9241-z
dc.identifier.epage420
dc.identifier.hkuros188334
dc.identifier.isiWOS:000300105300001
dc.identifier.issn1936-0533
2011 Impact Factor: 2.645
2011 SCImago Journal Rankings: 0.244
dc.identifier.issue1
dc.identifier.openurl
dc.identifier.spage419
dc.identifier.urihttp://hdl.handle.net/10722/136094
dc.identifier.volume5
dc.languageeng
dc.publisherSpringer New York LLC. The Journal's web site is located at http://www.springer.com/west/home/medicine?SGWID=4-10054-70-173733513-0
dc.relation.ispartofHepatology International
dc.rightsThe original publication is available at www.springerlink.com
dc.subjectMedical sciences
dc.subjectEndocrinology
dc.titleImpact of antiviral therapy on the survival outcome of patients after major hepatectomy for hepatitis B-related hepatocellular carcinoma
dc.typeConference_Paper